Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the annual meeting of stockholders held by Precision BioSciences, Inc. on May 4, 2023. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol DTIL.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 74,030,582 shares were present at the meeting, representing approximately 66% of the outstanding common stock as of the March 9, 2023 record date. The following proposals were approved:
- Item 1 (Election of Directors): Michael Amoroso and Geno Germano were elected as Class I directors to serve until the 2026 annual meeting.
- Item 2 (Auditor Ratification): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2023, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Michael Amoroso received 40,370,180 votes FOR, with 12,559,294 votes WITHHELD.
- Geno Germano received 38,629,199 votes FOR, with 14,300,275 votes WITHHELD.
- Both directors faced 21,101,108 broker non-votes.
- Deloitte & Touche LLP received 72,281,763 votes FOR, 1,690,384 votes AGAINST, and 58,435 votes ABSTAINED.
- There were zero broker non-votes for the auditor ratification proposal.